Lilly inflates US facility investment spending by $4.5bn
Having already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante.
Newsletters and Deep Dive digital magazine
Having already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante.
BioNTech's plan to shed 22% of its workforce and stop COVID-19 vaccine production has earned it a rebuke from Germany's third-largest labour union.
Shares in Novo Nordisk rose this morning after its highly anticipated first-quarter results revealed better-than-expected uptake of oral Wegovy.
Arvinas and Pfizer's Veppanu is the first PROTAC – and third oral SERD for breast cancer – to be approved by the FDA.
Moderna saw its Q1 sales nearly triple to $389m, almost a threefold rise on the same period of 2025, with international markets driving the increase.
Editor's Picks
Newsletters and Deep Dive
digital magazine